跳至主要内容
临床试验/NCT00051038
NCT00051038已完成2 期

A Phase II Study of the Safety and Efficacy of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients Who Have Hepatitis B Viremia While Being Treated With Lamivudine

Bristol-Myers Squibb5 个研究点 分布在 1 个国家开始时间: 2002年9月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
试验地点
5

研究概览

简要总结

The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, when being added to lamivudine, in the treatment of adults with chronic hepatitis B infection who are co-infected with HIV.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Documented history of co-infection with HIV and HBV
  • •Stable Anti Retroviral Therapy regimen containing lamivudine 150 mg BID for at least 24 weeks prior to enrollment;
  • •Documented HBV viremia on screening and at least at 4 weeks prior to screening
  • •HBe Ag-positive or HBe Ag-negative / anti-HBe-positive
  • •HIV viral load below 400 copies/mL by the Roche Amplicor(TM) 1.5 HIV PCR assay at screening and equally low at least 12 weeks prior to screening
  • •Absence of Co-Infection with hepatitis C virus (HCV) or hepatitis D virus (HDV)
  • •Absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease
  • •Less that 1/2 weeks of prior therapy with nucleoside/nucleotide analogue (excluding lamivudine) with activity against HBV (including e.g. famciclovir, tenofovir, ganciclovir, adefovir). No receipt of any of these therapies within 24 weeks prior to randomization into this study.

排除标准

  • 未提供

研究者

发起方
Bristol-Myers Squibb
申办方类型
Industry

研究点 (5)

Loading locations...

相似试验